What are the recent financial highlights of BALAXI PHARMA LTD?

BALAXI PHARMA LTD recently reported a total revenue of ₹241.29 Cr and a net profit margin of -0.99%. These metrics reflect the company’s consistent financial performance.

What are the key financial metrics of BALAXI PHARMA LTD?

Key financial metrics include a trailing P/E ratio of 12.251461, forward P/E of , book value of ₹39.51, price-to-book ratio of 1.5907365, and a market capitalization of ₹3.20 billion.

What does BALAXI PHARMA LTD do?

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. Balaxi Pharmaceuticals Limited was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Balaxi

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Balaxi

Latest updates related to Balaxi

Sr No.	Title	Sentiment
1	Balaxi Pharma Consolidated December 2024 Net Sales at Rs 73.29 crore, up 20.57% Y-o-Y Moneycontrol	🔄
2	Small-cap stock Balaxi Pharma jumps 7% after this overseas business update Mint	🔄
3	Bulk deals: Unico Global Opportunities Fund buys 8.3% stake in Balaxi Pharma, Malabar India picks up 1.15% stake TradingView	🔄
4	Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues Simply Wall St	🔄
5	Balaxi Pharma Standalone December 2024 Net Sales at Rs 11.16 crore, down 12.14% Y-o-Y Moneycontrol	🔄
6	Balaxi Pharmaceuticals announces global expansion Zee Business	🔄
7	Balaxi Pharma edges higher after board approves stock split proposal Business Standard	🔄
8	Balaxi Pharma to invest Rs 85 crore in new plant at Jadcherla The New Indian Express	🔄
9	Balaxi Pharmaceuticals consolidated net profit rises over 28 percent in Q2FY23 The Financial Express	🔄
10	Balaxi Pharmaceuticals growth remains robust on back of Geographical Expansions ANI News	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

BIGBLOC MHRIL KPITTECH OMAXE ACLGATI POLYPLEX BOSCHLTD GIRIRAJ DAMODARIND BANARISUG